Pharma License Agreement definition

Pharma License Agreement means the agreement between Danisco and Dyadic dated December 31, 2015, a redacted copy of which has been provided to BDI Pharmaceuticals for review in advance of executing this Agreement.

Pharma License Agreement means the pharma license agreement entered into between Dyadic and Danisco US, Inc on 31 December 2015. Products means Target Indicators products which apply, incorporate, fall within the scope of, or are created, supplied or used in accordance with any of the Sub-Licensed IP. Quarter means the three month periods ending on 31 March, 30 June, 30 September and 31 December. Registration Costs mean all fees, costs and expenses (including patent attorney and legal fees and expenses) incurred by Dyadic in the obtaining of grants of Patent Rights in the Territory and maintaining the same, including all expenses incurred in making and prosecuting patent applications and dealing with any opposition to any application for such registrations or any challenge to the validity of any such registrations Regulatory Approval mean the approval of the applicable Regulatory Authority necessary for the marketing and sale of a product for a particular indication in a country, excluding separate pricing or reimbursement approvals that may be required, and including the expansion or modification of the label for such indication. Regulatory Authority means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the marketing and sale of a pharmaceutical product in a country, including the United States Food and Drug Administration. Royalties means the amounts payable or paid by Novovet pursuant to clause 4.1(b). Sub-Licensees mean any Third Party to whom Novovet has granted a sub-licence of the Sub-Licensed IP pursuant to clause 3.1. Sub-Licensed IP means the Intellectual Property Rights which Dyadic either owns or has been granted rights under certain Patent Rights and Know-How under the Pharma License Agreement relating to the generation and use of its C1 Expression Technology which is necessary to enable Novovet to Commercialise the Sub-Licensed IP in the Field solely to develop, manufacture and sell the Target Indicators Products and includes the Patent Rights set out in Schedule 2, the Know-How set out in Schedule 3 and the Confidential Information relating to those Patent Rights and the Know-How.

Examples of Pharma License Agreement in a sentence

• For the avoidance of doubt, this includes the provisions of Section 10.7 of the Pharma License Agreement regarding resolution of disputes.

• Sublicensee acknowledges that it has read the Pharma License Agreement entered into between Danisco US Inc.

• Sublicensee acknowledges that it has read the Pharma License Agreement entered into between Danisco US Inc, and Dyadic International, Inc.

• If necessary and when requested, BDI Pharmaceuticals shall (i) sign and execute all such forms and documents as may be necessary to assure and perfect Dyadic’s rights (or rights of Danisco, if required by the Pharma License Agreement) in the Product IP, and (ii) cause its directors, employees, researchers, students, consultants and/or contractors, the Licensed Parties and Sublicensees to sign and execute all such forms and documents as may be necessary to perfect the Product IP.

• If receptacles are full, then in that event, garbage/trash and disposable shall be placed in thrash bags for City to dispose of.

• This license grant shall be subject to the terms of that certain Pharma License Agreement, dated December 31, 2015, between Licensor, Danisco US, Inc.

• For the avoidance of doubt, nothing in this agreement prohibits Novovet from sub-contracting either Luina or Dyadic to provide services on a fee for services basis provided that such services are provided on behalf of Novovet on an arms-length basis and in accordance with any obligations set out in the Shareholders’ Agreement and which are subject to the Pharma License Agreement.

• Furthermore, the author attended to an internal education of the SCA model for project management – PRIME.When the context of the research area had been established and an understanding started to emerge - an informal, unstructured interview was conducted with the HR Competence Devel- opment Manager in order to obtain a wider understanding of the area of motivation within the particular organization and to deeper explore the research questions.

• Subject to the Pharma License Agreement Dyadic is responsible to pay for all Patent Registration Costs relating to its Patent Rights, however (Novovet) will be responsible to pay for all Patent Registration Costs relating to Patents and Patent applications filed by Novovet which are based on the Target Indicators Products.

• Tax revenues are to be collected by the County and deposited to the respective General Fund and applied as provided in the Certificate.